香港股市 已收市

Immunovant, Inc. (IMVT)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
37.00+1.01 (+2.81%)
收市:04:00PM EST
37.02 +0.02 (+0.05%)
收市後: 08:00PM EST
全螢幕
交易股價資料並非來自所有市場
前收市價35.99
開市35.94
買盤36.99 x 1000
賣出價37.19 x 900
今日波幅35.94 - 37.46
52 週波幅14.05 - 45.58
成交量885,219
平均成交量1,554,839
市值5.376B
Beta 值 (5 年,每月)0.74
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-1.81
業績公佈日2024年5月13日 - 2024年5月27日
遠期股息及收益率無 (無)
除息日
1 年預測目標價50.71
  • Zacks

    Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus

    Immunovant (IMVT) gains 3% on encouraging fiscal third-quarter 2024 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.

  • InvestorPlace

    7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024

    As 2023 wrapped up, Russell 2000 stocks, mirroring the dynamics of small-to-mid-cap companies, showed resilience, outperforming their initial stance. The iShares Russell 2000 ETF (NYSEARCA:IWM), a key barometer for these stocks, boasts over $60 billion in assets and a robust daily trading volume surpassing 40 million, setting an impressive stage for these agile market players. Entering 2024, the spotlight intensifies on Russell 2000 stocks. Despite posting a commendable 12.9% average return last

  • Insider Monkey

    Should You Invest in Immunovant (IMVT)?

    Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The fund advanced 7.69% (Institutional Shares) in the quarter compared to a 6.96% gain for the Russell 3000 Health Care Index and an 11.69% increase for the S&P 500 Index. […]